MESSAGE FROM THE CEO

Welcome to OxThera’s website! We at OxThera are pioneering a novel approach for the treatment of primary hyperoxaluria, or PH for short. We are led by a dedicated and highly qualified team with decades of experience in biologics drug development, manufacturing and rare disease drug commercialization. Together with the support and funding from an experienced consortium of life science venture capital funds, we have been able to fulfill our commitment to helping patients with this severe genetic disease.

Our lead product candidate Oxabact® is being developed to be a safe, well-tolerated and easy-to-use treatment for PH patients. Our innovative approach addresses an unmet medical need to enhance enteric oxalate excretion that should effectively lower urinary and plasma oxalate concentrations and eventually break down oxalate crystal deposits in the body.

Oxabact® is now in a pivotal Phase III clinical trial at nine hospitals in Europe, North Africa and US, to confirm safety and efficacy in treatment of PH. The study is fully enrolled and top line data is expected mid-2021. Furthermore, we have recently completed a 24-month interim analysis of PH patients with End-Stage-Kidney-Disease (ESKD) on stable dialysis regimen undergoing up to 36 months of therapy of Oxabact®. The study met the primary endpoint to stabilize or reduce plasma oxalate levels and normalized cardiac function.

Our goal is to complete our phase III study and, if we have positive results, seek approval in both the US and Europe. We are excited about the potential that our therapy has to positively impact patients suffering from PH and prospects for Oxabact® to become an important therapeutic option in the future.
We invite you to learn more about the work we are doing.

Matthew Gantz

message-from-the-ceo